17:59 , Aug 23, 2018 |  BC Innovations  |  Translation in Brief

LRRK2 looming larger

Researchers from the University of Pittsburgh have identified a link between LRRK2 activity and idiopathic forms of Parkinson’s disease, further broadening the potential patient population for LRRK2 inhibitors in development, including two clinical compounds from...
15:35 , Jul 27, 2018 |  BC Week In Review  |  Company News

GSK, 23andMe partner on target, drug discovery

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will focus near-term R&D on label expansions plus first-in-class antibody-drug conjugate (ADC) GSK2857916 for multiple myeloma. The news came on July 25, when the pharma provided an R&D update, announced 2Q18...
23:14 , Jul 25, 2018 |  BC Extra  |  Company News

GSK's near-term R&D prospects include an ADC as it pivots to immunology

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will focus near-term R&D on label expansions plus first-in-class antibody-drug conjugate (ADC) GSK2857916 for multiple myeloma. The news came on Wednesday, when the pharma provided an R&D update, announced 2Q18 earnings...
15:30 , Jul 25, 2018 |  BC Innovations  |  Distillery Therapeutics

Gastrointestinal; autoimmune disease

INDICATION: Colitis; Crohn disease Mouse studies suggest inhibiting LRRK2 could help treat colitis and Crohn disease. In dendritic cells from eight Crohn patients, four LRRK2 inhibitor tool compounds decreased levels of inflammatory cytokines compared with...
18:51 , May 17, 2018 |  BC Innovations  |  Translation in Brief

A LRRK-ing link

In a pair of studies, researchers from Icahn School of Medicine at Mount Sinai identified links between Parkinson’s disease and inflammatory bowel disease that could spur the development of existing therapies for new indications. In...
15:00 , Dec 22, 2017 |  BC Week In Review  |  Clinical News

FDA lifts hold on Denali PD candidate

Denali Therapeutics Inc. (NASDAQ:DNLI) said FDA lifted a partial clinical hold on a Phase I study of Parkinson's disease candidate DNL201. It is a leucine-rich repeat kinase 2 (LRRK2) inhibitor. The agency placed the hold...
21:25 , Dec 21, 2017 |  BC Extra  |  Clinical News

FDA lifts hold on Denali's PD candidate

Denali Therapeutics Inc. (NASDAQ:DNLI) said FDA lifted a partial clinical hold on a Phase I study of Parkinson's disease candidate DNL201. It is a leucine-rich repeat kinase 2 (LRRK2) inhibitor. The agency placed the hold...
02:13 , Dec 14, 2017 |  BC Week In Review  |  Financial News

Denali raises $250M in IPO

Denali Therapeutics Inc. (NASDAQ:DNLI) raised $250 million through the sale of 13.9 million shares at $18 in an IPO. Underwriters were Goldman Sachs, Morgan Stanley, JPMorgan and Evercore ISI. The price is at the midpoint...
16:41 , Dec 8, 2017 |  BC Extra  |  Financial News

Denali climbs after $250M IPO

Denali Therapeutics Inc. (NASDAQ:DNLI) jumped $3.45 (19%) to $21.45 in its first day of trading Friday after it raised $250 million through the sale of 13.9 million shares at $18 in an IPO. Underwriters were...
19:14 , Nov 17, 2017 |  BC Week In Review  |  Financial News

Neurology play Denali planning $100M IPO

According to an SEC filing, neurodegenerative disease company Denali Therapeutics Inc. (South San Francisco, Calif.) is seeking to raise $100 million in an IPO on NASDAQ. Goldman Sachs, Morgan Stanley, JPMorgan and Evercore are underwriting...